Archive: Company News
Company News: Curetis: Novel Products and Study Data to be Presented at ECCMID 2018
— Introduction of Unyvero UTI Application Cartridge
— Update on A30 RQ Analyzer to be provided
— MGI/Curetis NGS Solution for Molecular Microbiology to be featured
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company and its subsidiary Ares Genetics GmbH will present novel products, data, and services during this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain, from April 21 – 24, 2018. Curetis and Ares Genetics can be found at booth #79, hall 10, during the conference.
Company News: Curetis Establishes U.S. Scientific Advisory Board
— U.S. Scientific Advisory Board formed with five renowned infectious disease specialists
— Expands Curetis’ scientific network and clinical expertise to support U.S. adoption of recently cleared Unyvero System and LRT Cartridge
Curetis N.V. (the “Company” and, together with Curetis GmbH and Curetis USA Inc., “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has established a dedicated U.S. Scientific Advisory Board.
Company News: New microDTTect solution improves diagnosis of periprosthetic infections
With the European launch of microDTTect Heraeus is now offering a novel solution for the diagnosis of periprosthetic infections. For the first time, orthopedists and microbiology labs can use a closed system allowing the contamination-free removal of bacterial biofilms on tissue and sample materials for further analysis. In the lab, microDTTect has demonstrated enhanced sensitivity and specificity in microbial detection of up to 94%, thereby significantly facilitating the correct diagnosis and treatment of biofilm-associated infections.
Company News: Curetis’ Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority
— Second market authorization for Unyvero Cartridges this year in Singapore
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that Acumen Research Laboratories Pte. Ltd. (Acumen), its partner for the commercialization of Unyvero in the ASEAN region, earlier today has received approval by the Singapore Health Sciences Authority (HSA) to market the Unyvero BCU Cartridge for bloodstream infections in Singapore.